<DOC>
	<DOCNO>NCT01894386</DOCNO>
	<brief_summary>This study evaluate pharmacokinetics FF , UMEC VI administer one inhaler ( two different strength UMEC ( 125 62.5microgram [ mcg ] ) FF/VI ( ICS/LABA ) UMEC/VI ( LAMA/LABA ) . Subjects receive four treatment , separate wash-out period 7-21 day dose four way crossover design . There 4 treatment period total . During treatment period , subject attend clinical unit Day -1 standard safety assessment addition familiarization inhaler . Each subject remain resident unit least 24 hour dose give Day 1 . Following completion four treatment period , follow visit take place 7 21 day follow final dose study medication .</brief_summary>
	<brief_title>Pharmacokinetic Study Healthy Volunteers Characterise Exposure Fluticasone Furoate ( FF ) , Vilanterol ( VI ) Umeclidinium ( UMEC ) Two Different Doses</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Chronic Disease</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<mesh_term>Fluticasone</mesh_term>
	<criteria>Safety Average Corrected QT Interval use Fridericia 's formula ( QTcF ) &lt; 450 msec screening . Forced Expiratory Volume 1 second ( FEV1 ) &gt; =80 % predict FEV1/Forced Vital Capacity ( FVC ) ratio &gt; =0.7 screen . Alanine transaminase ( ALT ) , alkaline phosphatase bilirubin &lt; =1.5x Upper Limit Normal ( ULN ) ( isolated bilirubin &gt; 1.5xULN acceptable bilirubin fractionate direct bilirubin &lt; 35 % ) . Population Male female 18 65 year age inclusive , time signing informed consent . Healthy determine responsible experienced physician , base medical evaluation include medical history , physical examination , laboratory test lung function testing . A subject clinical abnormality laboratory parameter outside reference range population study may include Investigator GSK medical monitor consider find unlikely introduce additional risk factor interfere study procedure outcome . Subjects current nonsmoker use tobacco product 6month period precede screen visit pack history &lt; =10 pack year . [ number pack year = ( number cigarette per day /20 ) x number year smoke ] Capable give write informed consent , include compliance requirement restriction list consent form . A female subject eligible participate follow : Nonchildbearing potential , females hormone replacement therapy ( HRT ) whose menopausal status doubt require use one contraception method woman childbearing potential use one contraception method . Body Mass Index ( BMI ) within range 18.033.0 kg/m2 ( inclusive ) . Safety Lactating pregnant female determine positive serum urine hCG test screen Day 1 . A supine mean heart rate outside range 4090 beat per minute ( bpm ) screening . Hepatic Disease Current chronic history liver disease , know hepatic biliary abnormality ( exception Gilbert 's syndrome asymptomatic gallstone ) history regular alcohol consumption within 6 month study define : average weekly intake &gt; 14 drink male &gt; 7 drink female . One drink equivalent 12 g alcohol : 12 ounce ( 360 mL ) beer , 5 ounce ( 150 mL ) wine 1.5 ounce ( 45 mL ) 80 proof distil spirit . Concurrent Disease History respiratory disease ( i.e . history asthmatic symptom ) last 10 year . A positive prestudy Hepatitis B surface antigen positive Hepatitis C antibody result within 3 month screen positive test HIV . Concurrent Medication Unable refrain use prescription nonprescription drug , include vitamin , herbal dietary supplement ( include St John 's Wort ) within 7 day ( 14 day drug potential enzyme inducer ) 5 halflives ( whichever longer ) prior first dose study medication , unless opinion Investigator GSK Medical Monitor medication interfere study procedure compromise subject safety . Population A positive prestudy drug/alcohol screen screen Day 1 . The subject participate clinical trial receive investigational product within following time period prior first dose day current study : 30 day , 5 halflives twice duration biological effect investigational product ( whichever longer ) , exposure four new chemical entity within 12 month prior first dose day . History sensitivity study medication , component thereof history drug allergy , opinion investigator GSK Medical Monitor , contraindicate participation . Unwillingness inability follow procedure outline protocol . Subject mentally legally incapacitate . The subject unable refrain consumption red wine , seville orange , grapefruit grapefruit juice pummelo , exotic citrus fruit , grapefruit hybrid fruit juice contain fruit 7 day prior first dose study medication duration study .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>GW642444 ( Vilanterol )</keyword>
	<keyword>GSK573719 ( Umeclidinium )</keyword>
	<keyword>GW685698 ( Fluticasone Furoate )</keyword>
	<keyword>pharmacokinetics</keyword>
	<keyword>Healthy subject</keyword>
</DOC>